Thymogam 250 mg Injection
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Thymogam 250 mg Injection contains anti-thymocyte immunoglobulin, an immunosuppressant that targets T lymphocytes. Its labelling describes it for preventing and delaying organ rejection after solid-organ (including kidney) transplantation, used with other therapies, and for the treatment of severe aplastic anaemia, where it suppresses the immune-mediated destruction of bone marrow cells. It is given only in a clinical or hospital setting.
Product Information
The following description reflects information associated with anti-thymocyte immunoglobulin and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for the prevention and treatment of organ rejection after solid-organ transplantation, including renal allograft rejection
- Described for the treatment of severe aplastic anaemia
- Described as targeting T lymphocytes to reduce immune-mediated damage and support normal cell production
Described Dosage & Administration
- Administered only by a doctor as an infusion in a clinical or hospital setting — not self-administered
- The dose and duration are set by the treating team according to the condition
- Stored between 2–8°C, away from light and excessive moisture, and out of the reach of children and pets
Described Side Effects
Commonly described side effects include:
- Urinary tract infection
- Stomach pain
- High blood pressure
- Nausea
- Fever, headache, and chills
- Anxiety
- Skin reactions
These are described as commonly temporary. Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- It is given under close monitoring in a hospital setting because of the risk of infusion reactions
- A missed dose should be discussed with the treating team rather than doubled
- Full medical records and current medicines should be shared with the transplant or haematology team
- Any severe or persistent side effect should be reviewed by a clinician
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it contains anti-thymocyte immunoglobulin and is used to prevent and treat organ transplant rejection and to treat severe aplastic anaemia, by targeting T lymphocytes. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling states it is administered by a doctor as an infusion in a clinical or hospital setting, at the dose and duration set by the treating team. It is stored between 2–8°C.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.